They suggested that the Nrf2-NF-κB signaling pathway is involved in regulating astrocyte activation in mice and that MSC-Exo may be a promising nanotherapeutic agent for the treatment of neurological diseases with hippocampal astrocyte alterations. Here, NFKB1 is linked to nervous system disorder.